Easterly Investment Partners LLC Has $3.14 Million Stake in Sanofi (NASDAQ:SNY)

Easterly Investment Partners LLC trimmed its holdings in Sanofi (NASDAQ:SNY) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,410 shares of the company’s stock after selling 333 shares during the period. Easterly Investment Partners LLC’s holdings in Sanofi were worth $3,136,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SNY. Boston Partners raised its holdings in shares of Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD boosted its stake in shares of Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of research reports. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Down 0.6 %

Shares of SNY stock traded down $0.32 during trading hours on Friday, hitting $51.41. 317,023 shares of the company were exchanged, compared to its average volume of 2,020,614. The firm has a market cap of $130.47 billion, a P/E ratio of 26.20, a P/E/G ratio of 1.31 and a beta of 0.61. Sanofi has a fifty-two week low of $45.13 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a 50 day simple moving average of $55.59 and a two-hundred day simple moving average of $52.14.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.55 EPS. Equities analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.